From: Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Techniques | Range of detection | Sensitivitya | References |
---|---|---|---|
Direct sequencing | All mutations in the interested region | 10–30% | [41] |
TheraScreen KRAS kit | 7 KRAS mutations in codons 12 and 13 | Approximately 1% | |
StripAssay | 10 KRAS mutations in codons 12 and 13 | 1% | |
SNaPshot | 12 KRAS mutations in codons 12 and 13 | 10% | |
Cobas | 19 KRAS mutations in codons 12, 13 and 61 | Approximately 1% | [46] |
Next generation sequencing | All clinical relevant KRAS mutations | 1–6% | |
Droplet digital PCR | 7 KRAS mutations in codons 12 and 13 | 0.01–0.05% | |
BEAMing | 16 KRAS mutations in codons 12, 13, 59, 61, 117 and 146 | 0.01% |